American Journal of Cardiology
Volume 96, Issue 11 , Pages 1589-1604 , 1 December 2005

The Editor’s Roundtable: Cyclooxygenase-2 Inhibitors and Cardiovascular Risk

  • Robert S. Bresalier, MD

      Affiliations

    • Professor and Chairman, Department of Gastrointestinal, Medicine and Nutrition, Birdie J and Lydia J Resoft Distinguished Professor in Gastrointestinal Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas
    • Dr. Bresalier is on the advisory board for Merck Research Laboratories, San Diego, California.
    • ,
  • Vincent E. Friedewald Jr, MD

      Affiliations

    • Visiting Professor and Director, New Media Center, University of Notre Dame, Notre, Dame, Indiana
    • Corresponding Author InformationCorresponding author: Tel: 574-631-7608; fax: 574-631-8209.
    • Drs. Friedewald, Rakel and Roberts have no relevant financial relationships to disclose.Conflicts of interest were resolved through peer review.
    • ,
  • Robert E. Rakel, MD

      Affiliations

    • Professor, Department of Family and Community Medicine, Baylor College of Medicine, Houston, Texas
    • Drs. Friedewald, Rakel and Roberts have no relevant financial relationships to disclose.Conflicts of interest were resolved through peer review.
    • ,
  • William C. Roberts, MD

      Affiliations

    • Medical Director, Baylor Heart and Vascular Institute, Baylor, University Medical Center, Dallas, Texas; Editor-in-Chief, The American Journal of Cardiology, and Dean, A. Webb Roberts Center for Continuing Medical Education of Baylor Health Care, System, Dallas, Texas
    • Drs. Friedewald, Rakel and Roberts have no relevant financial relationships to disclose.Conflicts of interest were resolved through peer review.
    • ,
  • Gary W. Williams, MD, PhD

      Affiliations

    • Chairman, Department of Medicine, Scripps Clinic, Medical Group; Vice President, Medicine Services and Academic Affairs Scripps Clinic Foundation, La Jolla, California.
    • Dr. Williams receives honoraria for speaking and consulting for Pfizer, Inc., New York, New York. He is on the advisory board and conducts research protocols for Pfizer.

Received 23 September 2005 ,Accepted 23 September 2005.

References 

  1. U.S. Food and Drug Administration (FDA) Alert. Available at: http://www.fda.gov/cder/drug/infopage/celebrex/celebrex-ptsk.htm. Accessed April 7, 2005.
  2. Vane JR . Inhibition of prostaglandin synthesis as a mechanism of action for the aspirin-like drugs . Nat New Biol . 1971;231:232–235
  3. Bombardier C, Laine L, Reicin A, Shapiro D, Burgos-Vargas R, Davis B, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis . N Engl J Med . 2000;343:1520–1528
  4. Solomon DH, Schneeweiss S, Glynn RJ, Kiyota Y, Levin R, Mogun H, et al. Relationship between selective cyclooxygenase-2 inhibitors and acute myocardial infarction in older adults . Circulation . 2004;109:2068–2073
  5. Ray WA , Stein C , Daugherty J , Hall K , Arbogast PG , Griffin MR . COX-2 selective non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease . Lancet . 2002;360:1071–1073
  6. Ray WA , Stein CM , Hall K , Daugherty JR , Griffin MR . Non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease (an observational cohort study) . Lancet . 2002;359:118–123
  7. Graham DJ, Campen D, Hui R, Spence M, Cheetham C, Levy G, et al. Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs (nested case-control study) . Lancet . 2005;365:475–481
  8. Johnsen SP, Larsson H, Tarone RE, McLaughlin JK, Nørgård B, Friis S, et al. Risk of hospitalization for myocardial infarction among users of rofecoxib, celecoxib, and other NSAIDs (a population-based case-control study) . Arch Intern Med . 2005;165:978–984
  9. Sudbo J Lee JJ, Lippman SM, Dannenberg AJ, Sagen S, Mork J, Ristimki A, Sudbo A Kildal W, Reith A. Non-steroidal anti-inflammatory drugs, tobacco and the risk of oral cancer. Abstract 4377 presented April 18 at the 96th annual meeting of the American Association for Cancer Research, Anaheim, CA.
  10. Bresalier RS, Sandler RS, Quan H, Bolognese JA, Oxenius B, Horgan K, et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial . N Engl J Med . 2005;352:1092–1102
  11. Juni P , Nartey L , Reichenbach S , Sterchi R , Dieppe PA , Egger M . Risk of cardiovascular events and rofecoxib (cumulative meta-analysis) . Lancet . 2004;364:2021–2029
  12. Solomon DH, Schneeweiss S, Glynn RJ, Kiyota Y, Levin R, Mogun H, et al. Relationship between selective cyclooxygenase-2 inhibitors and acute myocardial infarction in older adults . Circulation . 2004;109:2068–2073
  13. Merck News Release. Available at: www.merck.com/newsroom/press_releases/product/2004_0930.html. Accessed August 3, 2005.
  14. Silverstein FE, Faich G, Goldstein JL, Simon LS, Pincus T, Whelton A, et al  Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis. The CLASS study: A randomized controlled trial . JAMA . 2000;284:1247–1255
  15. Celecoxib [package insert] . Chicago, Il: GD Searle LLC, a subsidiary of Pharmacia Corporation; 2002; August
  16. Solomon SD, McMurray JJ, Pfeffer MA, Wittes J, Fowler R, Finn P, et al. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention . N Engl J Med . 2005;352:1071–1080
  17. Levin B. FDA Advisory Board Committee Meeting. February 17, 2005: Gaithersburg, MD.
  18. Clinical Trials Details. Available at: http://www.clinicaltrials.gov/ct/show/NCT00007189?order=1. Accessed August 3, 2005.
  19. Martin BK , Meinert CL , Breitner JC  ADAPT Research Group . Double placebo design in a prevention trial for Alzheimer’s disease . Control Clin Trials . 2002;23:93–99
  20. NIH Press Release on Suspension. Available at: http://www.nih.gov/news/pr/dec2004/od-20.htm. Accessed August 3, 2005.
  21. NIH Clinical Trials. Alzheimer’s Disease Anti-inflammatory Prevention Trial (ADAPT). Available at http://www.clinical%20trials.gov/ct/show/NCT00007189?order=1. Accessed August 3, 2005.
  22. Nussmeier NA, Whelton AA, Brown MT, Langford RM, Hoeft A, Parlow JL, et al. Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery . N Engl J Med . 2005;352:1081–1091
  23. Farkouh ME, Kirshner H, Harrington RA, Ruland S, Verheugt FW, Schnitzer TJ, et al  Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes (randomized controlled trial) . Lancet . 2004;364:675–684
  24. Baron JA, Cole BF, Sandler RS, Haile RW, Ahnen D, Bresalier R, et al  A randomized trial of aspirin to prevent colorectal adenomas . N Engl J Med . 2003;348:891–899
  25. Ott E, Nussmeir NA, Duke PC, Feneck RO, Alston RP, Snabes MC, et al. Efficacy and safety of the cyclooxygenase 2 inhibitors parecoxib and valdecoxib in patients undergoing coronary bypass surgery . J Thorac Cardiovasc Surg . 2003;125:1481–1492
  26. Furberg CD , Psaty BM , FitzGerald GA . Parecoxib, valdecoxib, and cardiovascular risk . Circulation . 2005;111:249
  27. Alsalameh S , Burian M , Mahr G , Woodcock BG , Geisslinger G . Review article (the pharmacological properties and clinical use of valdecoxib, a new cyclo-oxygenase-2-selective inhibitor) . Aliment Pharmacol Ther . 2003;17:489–501
  28. February 16–18, 2005 Joint Meeting with the Arthritis Drug Advisory Committee. Transcript of February 17, 2005. Available at: http://www.fda.gov/ohrms/dockets/ac/05/transcripts/2005–4090T2.htm. Accessed August 3, 2005.
  29. Food and Drug Administration. April 6, 2005. Available at: http://www.fda.gov/cder/drug/infopage/COX2/NSAIDdecisionMemo.pdf. Accessed August 3, 2005.
  30. Fitzgerald GA , Patrono C . The coxibs, selective inhibitors of cyclooxygenase-2 . N Engl J Med . 2001;345:433–442
  31. Fitzgerald GA . Coxibs and cardiovascular disease . N Engl J Med . 2004;351:1709–1711
  32. Cheng Y, Austin SC, Rocca B, Koller BH, Coffman TM, Grosser T, et al. Role of prostacyclin in the cardiovascular response to thromboxane A2 . Science . 2002;296:539–541
  33. Ridker PM , Cushman M , Stampfer MJ , Tracy RP , Hennekens CH . Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men . N Engl J Med . 1997;336:973–979
  34. Ross R . Atherosclerosis—an inflammatory disease . N Engl J Med . 1999;340:115–126
  35. Weyland CM, Goronzy JJ, Goronzy JJ, Liuzzo G, Kopecky SL, Holmes DR, et al. T-cell immunity in acute coronary syndromes . Mayo Clin Proc . 2001;76:1011–1020
  36. Libby P . Inflammation in atherosclerosis . Nature . 2002;420:868–874
  37. Chenevard R, Hurlimann D, Bechir M, Enseleit F, Spieker L, Hermann M, et al  Selective COX-2 inhibition improves endothelial function in coronary artery disease . Circulation . 2003;107:405–409
  38. Walter M , Jacob RF , Day CA , Dahlborg R , Weng Y , Mason RP . Sulfone COX-2 inhibitors increase susceptibility of human LDL and plasma to oxidative modification (comparison to sulfonamide COX-2 inhibitors and NSAIDs) . Atherosclerosis . 2004;177:235–243
  39. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL, et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure . Hypertension . 2003;42:1206–1252
  40. Whelton A , White WB , Bello AE , Puma JA , Fort JG . Effects of celecoxib and rofecoxib on blood pressure and edema in patients ≥65 years of age with systemic hypertension and osteoarthritis . Am J Cardiol . 2002;90:959–963
  41. MMWR: Comorbidity of high blood pressure and arthritis. Available at: http://www.cdc.gov/mmwr/preview/mmwrhtml/00001503.htm. Accessed August 3, 2005.
  42. Whelton A , Fort JG , Puma JA , Normandin D , Bello AE , Verburg KM . Cyclooxygenase-2-specific inhibitors and cardiorenal function (a randomized, controlled trial of celecoxib and rofecoxib in older hypertensive osteoarthritis patients) . Am J Ther . 2001;8:85–95
  43. White WB , Kent J , Taylor A , Verburg KM , Lefkowich JB , Whelton A . Effects of celecoxib on ambulatory blood pressure in hypertensive patients on ACE inhibitors . Hypertension . 2002;39:929–934
  44. Sowers JR, White WB, Pitt B, Whelton A, Simon L, Winner N, et al. Rofecoxib, but not celecoxib or naproxen, increases mean 24-hour systolic blood pressure in treated hypertensive patients with osteoarthritis and type-2 diabetes mellitus . Arch Intern Med . 2005;165:161–168
  45. Ridker PM, Cook NR, Lee I-M, Gordon D, Gaziano M, Manson JE, et al. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women . N Engl J Med . 2005;352:1293–1304
  46. Eidelman RS , Hebert PR , Weisman SE , Hennekens CH . An update on aspirin in the primary prevention of cardiovascular disease . Arch Intern Med . 2003;163:2006–2010
  47. Catella-Lawson F, Muredach PR, Kapoor SC, Cucchiara AJ, DeMarco S, Tournier B, et al. Cyclooxygenase inhibitors and the antiplatelet effects of aspirin . N Engl J Med . 2001;345:1809–1817
  48. MacDonald TM , Wei L . Effect of ibuprofen on cardioprotective effect of aspirin . Lancet . 2003;306:573–574
  49. Lanas A, Bresalier RS, Sandler R, Bolognese J, Qan H, Oxenius B, et al. Upper gastrointestinal events associated with rofecoxib in a colorectal adenoma chemoprevention trial . Gastroenterology . 2005;129:371
  50. Capone ML, Tacconelli S, Sciulli MG, Grana M, Ricciotti E, Minuz P, et al. Clinical pharmacology of platelet, monocyte, and vascular cyclooxygenase inhibition by naproxen and low-dose aspirin in healthy subjects . Circulation . 2004;109:1468–1471
  51. Hermann M , Krum H , Ruschitzka F . To the heart of the matter (coxibs, smoking, and cardiovascular risk) . Circulation . 2005;112:941–945
  52. Kelly JP , Kaufman DW , Jurgelon JM , Sheehan J , Koff RS , Shapiro S . Risk of aspirin-associated major upper-gastrointestinal bleeding with enteric-coated or buffered product . Lancet . 1996;348:1413–1416
  53. Rahme E , Barkun A , Toubouti Y , Rochon S , LeLorier J . Do proton pump inhibitors (PPI) infer additional gasrointestinal protection in patients given celecoxib? . Pharmacoepidemiology and Drug Safety . 2005;14:S189
  54. Laine L , Maller ES , Yu C , Quan H , Simon T . Ulcer formation with low-dose enteric-coated aspirin and the effect of COX-2 selective inhibition (a double blind trial) . Gastroenterology . 2004;127:395–402
  55. Graham DY, Agrawal NM, Campbell DR, Haber MM, Collis C, nLukasik NL, et al. Ulcer prevention in long-term users of nonsteroidal anti-inflammatory drugs (results of a doubleblind, randomized, multicenter, active- and placebo-controlled study of misoprostol vs lansoprazole) . Arch Intern Med . 2002;162:169–175
  56. Dannenberg AJ , Subbaramaiah K . Targeting cyclooygenase-2 in human neoplasia (rationale and promise) . Cancer Cell . 2003;4:431–443
  57. Steinbach G, Lynch PM, Phillips RKS, Wallace MH, Hawk E, Gordon GB, et al. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis . N Engl J Med . 2000;342:1946–1952
  58. Celecoxib Treatment for Lung Cancer. Available at: http://www.clinicaltrials.gov/ct/show/NCT00108186?order=1. Accessed August 3, 2005.
  59. Johnson AG , Nguyen TV , Day RO . Do nonsteroidal anti-inflammatory drugs affect blood pressure? A meta-analysis . Ann Intern Med . 1994;121:289–300
  60. Topol EJ . Failing the public health—rofecoxib, Merck, and the FDA . N Engl J Med . 2004;351:1707–1709
  61. Chandrasekharan NV , Dai H , Roos LT , Evanson NK , Tomsik J , Simmon DL . COX-3, a cyclooxygenase-1 variant inhibited by acetaminophen and other analgesic/antipyretic drugs (CLoning, structure and expression) . Proc Natl Acad Sci USA . 2002;99:13926–13931
  62. Perneger TV , Whelton PK , Klag MJ . Risk of kidney failure associated with the use of acetaminophen, aspirin, and nonsteroidal antiinflammatory drugs . N Engl J Med . 1994;331:1675–1679
  63. Curhan GC , Knight EL , Rosner B , Hankinson SE , Stampfer MJ . Lifetime nonnarcotic analgesic use and decline in renal function in women . Arch Intern Med . 2004;164:1519–1524
  64. Forman JP , Stampfer MJ , Curhan GC . Non-narcotic analgesic dose and risk of incident hypertension in US women . Hypertension . 2005;46:500–507
  65. Garcia Rodriguez LA , Hernandez-Diaz S . Relative risk of upper gastrointestinal complications among users of acetaminophen and nonsteroidal anti-inflammatory drugs . Epidemiology . 2001;12:570–576
  66. Rahme E , Pettitt D , LeLorier J . Determinants and sequelae associated with utilization of acetaminophen versus traditional nonsteroidal antiinflammatory drugs in an elderly population . Arthritis Rheum . 2002;46:3046–3054
  67. Woolf AD, Zeidler H, Haglund U, Carr AJ, Chaussade S, Cucinotta D, et al. Musculoskeletal pain in Europe (its impact and a comparison of population and medical perceptions of treatment in eight European countries) . Ann Rheum Dis . 2004;63:342–347
  68. Pincus T , Swearingen C , Cummins P , Callahan LF . Preference for nonsteroidal antiinflammatory drugs versus acetaminophen and concomitant use of both drugs in patients with osteoarthritis . J Rheumatol . 2000;27:1020–1027

 This activity is supported by an educational grant from Pfizer, Inc., New York, New York.Disclosure

PII: S0002-9149(05)01620-6

doi: 10.1016/j.amjcard.2005.09.069

American Journal of Cardiology
Volume 96, Issue 11 , Pages 1589-1604 , 1 December 2005

Article Tools

* Image Usage & Resolution